	Corrigendum to "SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer" [Radiother. Oncol. 155 (2021) 278-284]. Radiother Oncol Holyoake DLP, Robinson M, Silva M, Grose D, McIntosh D, Sebag-Montefiore D, Radhakrishna G, Mukherjee S, Hawkins MA. PMID: 42214926 [PubMed - as supplied by publisher]
	Current opinions on CEA in the diagnosis and prognosis of colorectal cancer. Transl Oncol Han Q, Zhu Y, Xing F, Xia Y. PMID: 42214175 [PubMed - as supplied by publisher]
	Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data. Cancer Rep (Hoboken) Cheng Y, Liu L, Gao Y, Wang Y, Zhu W, Chen H, Qin J, Zhang Y. PMID: 42213496 [PubMed - indexed for MEDLINE]
	Cancer vaccines: comprehensive review. BJS Open Clifford RE, Manu N, Yang Q, Arif Z, Aggen D, Bryan ME, Gupta A, Shaw H, Church D, Corrie P, Savelyeva N, Ottensmeier C, Danson S, Jones R. PMID: 42213481 [PubMed - indexed for MEDLINE]
	Fusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression. Clin Transl Med Zhao F, An R, Yu S, Ma Y, Liu W, Sheng C, Xie X, Zhang J. PMID: 42212696 [PubMed - indexed for MEDLINE]
	Neutrophil Extracellular Traps in Pancreatic Ductal Adenocarcinoma: A Vicious Cycle in the Tumor Microenvironment and Targeted Interventions. Int J Biol Sci Zhao L, Yuan H, Chen Z, Xia X, Tian X, Wang S. PMID: 42212337 [PubMed - indexed for MEDLINE]
	Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy versus gemcitabine and nab-paclitaxel as first-line treatment for recurrent or metastatic pancreatic ductal adenocarcinoma: a randomized, open-label, multicenter, phase III clinical trial (WGOG-PAN 006/ICSBR-2). Front Immunol Wang X, Zhang P, Cao D, Xu H. PMID: 42212134 [PubMed - indexed for MEDLINE]
	Multi-omic profiles of neuroendocrine neoplasms of the pancreas: an integrated landscape. Mol Cancer Bevere M, Gkountakos A, Valentinuzzi S, De Fabritiis S, Wong CS, De Robertis R, Mattiolo P, Gentiluomo M, Fassan M, Pea A, Crinò SF, Simbolo M, Mafficini A, Campa D, Cingarlini S, Landoni L, Lawlor RT, Salvia R, D'Onofrio M, Milella M, Adsay V, Brosens LA, Heaphy CM, Hong SM, Singhi AD, Scarpa A, Luchini C. PMID: 42210310 [PubMed - as supplied by publisher]
	Machine learning for postoperative complication prediction and early recurrence risk assessment across cancer types: a systematic review and meta-analysis. Cancer Cell Int Chen W, Liu X, Wu Z, Tan H, Yu F, Wang D, Gao H, Chen Z. PMID: 42210259 [PubMed]
	Quantitative MRI of pancreatic parenchyma in intraductal papillary mucinous neoplasm: association with risk stratification based on guideline features. Eur Radiol Maeba K, Kanki A, Fukukura Y, Yasokawa K, Sotozono H, Yamamoto A, Moriya K, Ueda Y, Tamada T. PMID: 42209832 [PubMed - as supplied by publisher]
	CT-derived body composition predicts futile upfront resection in pancreatic cancer: a multicenter study. Eur Radiol Dai GX, Zhou Y, Zhang QB, Zhang S, Li Y, Wang X, Liu D, Zhang K, Meng XP, Wang J, Chen FM. PMID: 42209831 [PubMed - as supplied by publisher]
	Metabolic plasticity in the pancreatic cancer metastatic cascade. Biochim Biophys Acta Rev Cancer Zhu B, Guo Y, Lu Y. PMID: 42208918 [PubMed - as supplied by publisher]
	Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors. Updates Surg Liao TK, Lu WH, Su PJ, Wang CJ, Chao YJ, Shan YS. PMID: 42207486 [PubMed - as supplied by publisher]
	Evaluation of the efficacy of plan adaptation in stereotactic body proton therapy for pancreatic cancer. J Appl Clin Med Phys Matsuo Y, Uchinami Y, Katoh N, Hashimoto T, Aoyama H, Nakazato K, Matsuura T, Miyamoto N, Takao S. PMID: 42206597 [PubMed - indexed for MEDLINE]
	Cancer Surveillance in Lynch Syndrome: A Scoping Review of International and National Guidelines. Genet Med McKenzie M, Quinn M, Stockley C, Wood M, Isherwood S, Quan ML. PMID: 42206489 [PubMed - as supplied by publisher]
	A machine learning-based interpretable model for predicting pancreatic cancer in chronic pancreatitis patients with focal pancreatic lesions. BMC Cancer Yi JH, Wang T, Bi YW, Xu JJ, Liu M, Chen GM, Li ZS, Wang D, Chai NL, Hu LH. PMID: 42204501 [PubMed - as supplied by publisher]
	Towards early detection of pancreatic cancer: The current status of cohort studies by the Diabetes-Pancreatic Ductal AdenoCarcinoma Working Group. Pancreatology Maitra A, Chari ST, Wu B, Van Den Eeden SK, Fisher W, Vege SS, Rinaudo JA, Feng Z, Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). PMID: 42203568 [PubMed - as supplied by publisher]
	Preoperative Serum Total Cholesterol Predicts Adjuvant Chemotherapy Completion After Pancreaticoduodenectomy for Pancreatic Cancer. Anticancer Res Hatta K, Nishimura S, Tanaka R, Shinkawa H, Nishio K, Kinoshita M, Tauchi J, Kurihara S, Ishizawa T. PMID: 42203346 [PubMed - indexed for MEDLINE]
	Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan-Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer. Anticancer Res Maeda K, Koyama S, Kawada K, Hayashi T, Yoshioka T, Ishida T, Fukuda H, Horikawa IO, Aizawa F, Niimura T, Yagi K, Goda M, Izawa-Ishizawa Y, Abe S, Ishizawa K. PMID: 42203343 [PubMed - indexed for MEDLINE]
	Tertiary lymphoid structures (TLS): The mechanism hub and therapeutic target of neoadjuvant immunotherapy for hepatocellular carcinoma. Crit Rev Oncol Hematol Wu Q, Jin L, Cao L, Zhang C, Dou C. PMID: 42202921 [PubMed - as supplied by publisher]

Articles 1 - 20 / 60254

Page 1 of 3013



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy